Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 225 Binney Street CAMBRIDGE MA 02142 |
Tel: | N/A |
Website: | https://www.biogen.com |
IR: | See website |
Key People | ||
Christopher A. Viehbacher President, Chief Executive Officer, Director | Charles E. Triano Senior Vice President, Head of Investor Relations | Michael R. McDonnell Chief Financial Officer, Executive Vice President |
Ginger Gregory Chief Human Resource Officer, Executive Vice President | Susan H. Alexander Executive Vice President, Chief Legal Officer, Secretary | Rachid Izzar Executive Vice President, Head of Global Product Strategy and Commercialization |
Adam James Keeney Executive Vice President, Head of Corporate Development | Nicole Murphy Executive Vice President - Pharmaceutical Operations and Technology | Priya Singhal Executive Vice President - Head of Development | Robin C. Kramer Senior Vice President, Chief Accounting Officer |
Business Overview |
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ. |
Financial Overview |
For the three months ended 31 March 2024, Biogen Inc revenues decreased 7% to $2.29B. Net income increased 1% to $393.4M. Revenues reflect Rest of World-Other revenues segment decrease of 42% to $184.6M, Rest of World segment decrease of 9% to $965.8M. Net Income benefited from Other Research and development decrease of 23% to $417.9M (expense), FV Adjustments of Financial Investments decrease of 61% to $30.6M (expense). |
Employees: | 7,570 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $37,134M as of Mar 31, 2024 |
Annual revenue (TTM): | $9,663M as of Mar 31, 2024 |
EBITDA (TTM): | $2,652M as of Mar 31, 2024 |
Net annual income (TTM): | $1,167M as of Mar 31, 2024 |
Free cash flow (TTM): | $1,284M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | $5,466M as of Mar 31, 2024 |
Shares outstanding: | 145,596,895 as of Apr 23, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |